Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 147 No. 3334 (2017)

First trimester combined screening for preeclampsia and small for gestational age – a single centre experience and validation of the FMF screening algorithm

  • Beatrice Mosimann
  • Chantal Pfiffner
  • Sofia Amylidi-Mohr
  • Lorenz Risch
  • Daniel Surbek
  • Luigi Raio
DOI
https://doi.org/10.4414/smw.2017.14498
Cite this as:
Swiss Med Wkly. 2017;147:w14498
Published
25.08.2017

Summary

AIM OF THE STUDY

Preeclampsia (PE) is associated with severe maternal and fetal morbidity in the acute presentation and there is increasing evidence that it is also an important risk factor for cardiovascular disease later in life. Therefore, preventive strategies are of utmost importance. The Fetal Medicine Foundation (FMF) London recently developed a first trimester screening algorithm for placenta-related pregnancy complications, in particular early onset preeclampsia (eoPE) requiring delivery before 34 weeks, and preterm small for gestational age (pSGA), with a birth weight <5th percentile and delivery before 37 weeks of gestation, based on maternal history and characteristics, and biochemical and biophysical parameters. The aim of this study was to test the performance of this algorithm in our setting and to perform an external validation of the screening algorithm.

MATERIAL AND METHODS

Between September 2013 and April 2016, all consecutive women with singleton pregnancies who agreed to this screening were included in the study. The proposed cut-offs of ≥1:200 for eoPE, and ≥1:150 for pSGA were applied. Risk calculations were performed with Viewpoint® program (GE, Mountainview, CA, USA) and statistical analysis with GraphPad version 5.0 for Windows.

RESULTS

1372 women agreed to PE screening; the 1129 with complete data and a live birth were included in this study. Nineteen (1.68%) developed PE: 14 (1.24%) at term (tPE) and 5 (0.44%) preterm (pPE, <37 weeks), including 2 (0.18%) with eoPE. Overall, 97/1129 (8.6%) screened positive for eoPE, including both pregnancies that resulted in eoPE and 4/5 (80%) that resulted in pPE. Forty-nine of 1110 (4.41%) pregnancies without PE resulted in SGA, 3 (0.27%) of them in pSGA. A total of 210/1110 (18.9%) non-PE pregnancies screened positive for pSGA, including 2/3 (66.7%) of the pSGA deliveries and 18/46 (39.1%) of term SGA infants.

CONCLUSION

Our results show that first trimester PE screening in our population performs well and according to expectations, whereas screening for SGA is associated with a high false positive rate.

References

  1. Knight M, Tuffnell D, Kenyon S, Shakespeare J, Gray R, Kurinczuk JJ, eds. on behalf of MBRRACE-UK. Surveillance of maternal deaths in the UK 2011–2013. Oxford: National Perinatal Epidemiology Unit, University of Oxford; 2015.
  2. Manktelow BN, Smith LK, Seaton SE, Hyman-Taylor P, Kurinczuk JJ, Field DJ, et al., on behalf of the MBRRACE-UK collaboration. MBRRACE-UK Perinatal Mortality Surveillance Report: UK Perinatal Deaths for Births from January to December 2014. Leicester: The Infant Mortality and Morbidity Studies, Department of Health Sciences, University of Leicester; 2016.
  3. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–7. doi:.https://doi.org/10.1053/j.semperi.2009.02.010
  4. Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al.; Lancet Ending Preventable Stillbirths Series study group; Lancet Stillbirth Epidemiology investigator group. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet. 2016;387(10018):587–603. doi:.https://doi.org/10.1016/S0140-6736(15)00837-5
  5. Lindqvist PG, Molin J. Does antenatal identification of small-for-gestational age fetuses significantly improve their outcome? Ultrasound Obstet Gynecol. 2005;25(3):258–64. doi:.https://doi.org/10.1002/uog.1806
  6. Ghossein-Doha C, van Neer J, Wissink B, Breetveld N, de Windt LJ, van Dijk AP, et al. Pre-eclampsia, an important female specific risk factor for asymptomatic heart failure. Ultrasound Obstet Gynecol. 2017;49(1):143–9.
  7. Sehgal A, Skilton MR, Crispi F. Human fetal growth restriction: a cardiovascular journey through to adolescence. J Dev Orig Health Dis. 2016;7(6):626–35. doi:.https://doi.org/10.1017/S2040174416000337
  8. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation. 2011;123(11):1243–62. doi:.https://doi.org/10.1161/CIR.0b013e31820faaf8
  9. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2):e003497; epub ahead of print. doi:.https://doi.org/10.1161/CIRCOUTCOMES.116.003497
  10. Fields JA, Garovic VD, Mielke MM, Kantarci K, Jayachandran M, White WM, et al. Preeclampsia and cognitive impairment later in life. Am J Obstet Gynecol. 2017;217(1):74.e1–11; epub ahead of print. doi:.https://doi.org/10.1016/j.ajog.2017.03.008
  11. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2 Pt 1):402–14. doi:.https://doi.org/10.1097/AOG.0b013e3181e9322a
  12. Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2013;41(5):491–9. doi:.https://doi.org/10.1002/uog.12421
  13. National Institute of Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. Clinical Guideline CG107. 2011. Available from: https://www.nice.org.uk/guidance/cg107.
  14. Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; 2013.
  15. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8–15. doi:.https://doi.org/10.1159/000341264
  16. Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. Fetal Diagn Ther. 2011;29(2):148–54. doi:.https://doi.org/10.1159/000321694
  17. O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016;214(1):103.e1–12. doi:.https://doi.org/10.1016/j.ajog.2015.08.034
  18. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther. 2013;33(1):16–27. doi:.https://doi.org/10.1159/000341712
  19. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn. 2015;35(2):183–91. doi:.https://doi.org/10.1002/pd.4519
  20. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;NEJMoa1704559; epub ahead of print. doi:.https://doi.org/10.1056/NEJMoa1704559
  21. Wright D, Akolekar R, Syngelaki A, Poon LCY, Nicolaides KH. A competing risks model in early screening for preeclampsia. Fetal Diagn Ther. 2012;32(3):171–8. doi:.https://doi.org/10.1159/000338470
  22. The Fetal Medicine Foundation. Assessment of risk for preeclampsia. Clinical algorithm. Available from: www.fetalmedicine.org/research/assess/preeclampsia
  23. Mosimann B, Amylidi-Mohr S, Höland K, Surbek D, Risch L, Raio L. Importance of Timing First-Trimester Placental Growth Factor and Use of Serial First-Trimester Placental Growth Factor Measurements in Screening for Preeclampsia. Fetal Diagn Ther. 2017; epub ahead of print. doi:.https://doi.org/10.1159/000455946
  24. Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, et al. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol. 2015;46(4):419–23. doi:.https://doi.org/10.1002/uog.14819
  25. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014;4(2):97–104.
  26. Purde MT, Baumann M, Wiedemann U, Nydegger UE, Risch L, Surbek D, et al. Incidence of preeclampsia in pregnant Swiss women. Swiss Med Wkly. 2015;145:w14175.
  27. Wu P, van den Berg C, Alfirevic Z, O’Brien S, Röthlisberger M, Baker PN, et al. Early pregnancy biomarkers in preeclampsia: a systematic review and meta-analysis. Int J Mol Sci. 2015;16(9):23035–56. doi:.https://doi.org/10.3390/ijms160923035
  28. Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting pre-eclampsia. Mol Aspects Med. 2007;28(2):227–44. doi:.https://doi.org/10.1016/j.mam.2007.04.002
  29. Crovetto F, Figueras F, Triunfo S, Crispi F, Rodriguez-Sureda V, Dominguez C, et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenat Diagn. 2015;35(2):183–91. doi:.https://doi.org/10.1002/pd.4519
  30. Ridding G, Schluter PJ, Hyett JA, McLennan AC. Influence of sampling site on uterine artery Doppler indices at 11-13+6 weeks gestation. Fetal Diagn Ther. 2015;37(4):310–5. doi:.https://doi.org/10.1159/000366060
  31. Ridding G, Hyett JA, Sahota D, McLennan AC. Assessing quality standards in measurement of uterine artery pulsatility index at 11 to 13 + 6 weeks’ gestation. Ultrasound Obstet Gynecol. 2015;46(3):299–305. doi:.https://doi.org/10.1002/uog.14732
  32. Mone F, Mulcahy C, McParland P, McAuliffe FM. Should we recommend universal aspirin for all pregnant women? Am J Obstet Gynecol. 2017;216(2):141.e1–5.
  33. Xu TT, Zhou F, Deng CY, Huang GQ, Li JK, Wang XD. Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis. J Clin Hypertens (Greenwich). 2015;17(7):567–73. doi:.https://doi.org/10.1111/jch.12541
  34. Elwood PC, Morgan G, Galante J, Chia JW, Dolwani S, Graziano JM, et al. Systematic review and meta-analysis of randomized trials to ascertain fatal gastrointestinal bleeding events attributable to preventive low-dose aspirin: no evidence of increased risk. PLoS One. 2016;11(11):e0166166. doi:.https://doi.org/10.1371/journal.pone.0166166
  35. Cruz-Lemini M, Crispi F, Valenzuela-Alcaraz B, Figueras F, Sitges M, Bijnens B, et al. Fetal cardiovascular remodeling persists at 6 months in infants with intrauterine growth restriction. Ultrasound Obstet Gynecol. 2016;48(3):349–56. doi:.https://doi.org/10.1002/uog.15767
  36. Chen CW, Jaffe IZ, Karumanchi SA. Pre-eclampsia and cardiovascular disease. Cardiovasc Res. 2014;101(4):579–86. doi:.https://doi.org/10.1093/cvr/cvu018

Most read articles by the same author(s)

1 2 > >>